Schutz Alexander, Zhang Qianzi, Bertapelle Kimberly, Beecher Nicholas, Long William, Lee Vei-Vei, Pan Wei, Arcaro Michael, Ghanta Ravi, Jimenez Ernesto, Ott David A, Loor Gabriel
Division of Cardiothoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
Department of Cardiovascular Surgery, Texas Heart Institute, Houston, TX, USA.
Interact Cardiovasc Thorac Surg. 2020 May 1;30(5):699-705. doi: 10.1093/icvts/ivaa010.
Del Nido cardioplegia (DNC) has been shown to be safe in adults with normal coronary arteries who are undergoing valve surgery. This study compared the effects of DNC versus traditional blood-based cardioplegia on postoperative complications in patients who underwent coronary artery bypass grafting (CABG).
A retrospective analysis was performed on 863 patients who underwent CABG with DNC (n = 420) or control cardioplegia (CC) (n = 443) between 2014 and 2017. The full cohort of DNC and CC recipients, as well as propensity score-matched pairs, was compared regarding preoperative risk variables and outcomes.
The DNC and CC groups showed no significant differences in mean cardiopulmonary bypass time (53.09 vs 52.10 min, P = 0.206) or aortic cross-clamp time (32.82 vs 33.28 min, P = 0.967). The groups also showed no difference in operative mortality (2.1% vs 2.5%, P = 0.734); however, DNC use resulted in lower rates of overall infections (1.7% vs 4.3%, P = 0.024), total sternal infections (0.9% vs 3.2%, P = 0.023), postoperative atrial fibrillation (23.8% vs 30.7%, P = 0.023) and postoperative ventricular tachycardia (0.5% vs 3.4%, P = 0.002). A propensity-matching analysis (n = 335 pairs) showed similar statistically significant decreases with DNC.
In this large cohort of CABG patients, DNC was shown as a safe alternative to CC and was associated with lower postoperative dysrhythmia and infection rates. These findings show that DNC is safe and effective in patients whose operative interventions may require only single-dosing cardioplegia; its use in longer cases should be further explored given its low complication rate.
对于接受瓣膜手术的冠状动脉正常的成年人,已证实德尔尼多心脏停搏液(DNC)是安全的。本研究比较了DNC与传统血液心脏停搏液对接受冠状动脉旁路移植术(CABG)患者术后并发症的影响。
对2014年至2017年间接受CABG并使用DNC(n = 420)或对照心脏停搏液(CC)(n = 443)的863例患者进行回顾性分析。比较了DNC和CC接受者的整个队列以及倾向评分匹配对的术前风险变量和结果。
DNC组和CC组在平均体外循环时间(53.09对52.10分钟,P = 0.206)或主动脉阻断时间(32.82对33.28分钟,P = 0.967)上无显著差异。两组在手术死亡率上也无差异(2.1%对2.5%,P = 0.734);然而,使用DNC导致总体感染率较低(1.7%对4.3%,P = 0.024)、胸骨全感染率较低(0.9%对3.2%,P = 0.023)、术后房颤发生率较低(23.8%对30.7%,P = 0.023)以及术后室性心动过速发生率较低(0.5%对3.4%,P = 0.002)。倾向匹配分析(n = 335对)显示使用DNC有类似的统计学显著降低。
在这个大型CABG患者队列中,DNC被证明是CC的安全替代方案,并且与较低的术后心律失常和感染率相关。这些发现表明,DNC在手术干预可能仅需要单次剂量心脏停搏液的患者中是安全有效的;鉴于其低并发症率,应进一步探索其在更长手术中的应用。